"Chile Pharmaceuticals & Healthcare Report Q4 2010" now available at Fast Market Research

Oct. 17, 2010 - PRLog -- In BMI's Q410 Business Environment Ratings (BERs) for the 17 markets of the Americas, Chile receives a composite pharmaceutical rating of 50.8, placing the country eighth in the matrix. BMI's Americas pharmaceuticals and healthcare coverage now includes Central America - Costa Rica, Panama, El Salvador, Guatemala, Honduras, Nicaragua and Belize. Generally speaking, Chile's attractiveness as a destination for pharmaceutical investment suffers from the fact that reimbursement is minimal, despite the recent expansion through the flagship Universal Access and Explicit Guarantees (AUGE) healthcare plan, in addition to low retail drug prices.

Nevertheless, Chile offers considerable longer-term benefits to foreign companies, as the absolute size of its drug market is expected to grow as public health coverage expands. The government continues to place attracting foreign investment high on its priority list. An infrastructure network which rivals that of many in the developed world is a major asset to the Chilean business climate and, together with a very open foreign trade regime, helps to maintain the country's reputation as an attractive foreign direct investment (FDI) destination. Although low by regional standards, corruption and criminal activity remains a nuisance and the new government will face significant challenges on these fronts.

BMI calculates that pharmaceutical sales in Chile reached a value of CLP580.42bn (US$1.04bn) in 2009, up from the CLP554.23bn (US$1.06bn) market size in 2008. BMI notes that as a result of the weak Chilean peso, 2009 drug market expenditure in US dollar terms experienced a -1.8% decline from its value in 2008. BMI also attributes the decline in Chile's pharmaceutical expenditure growth in 2009 to the economic downturn and the resultant drop in the country's GDP growth - from 3.69% in 2008 to -1.53% in 2009. Drug expenditure in Chile represented 0.63% of GDP in 2009, while per-capita spending stood at a low US$61.3.

In 2010, we expect pharmaceutical sales to reach a value of CLP623.82bn (US$1.17bn), experiencing a 7.49% growth in local currency terms and 12.4% in US dollar terms, which we attribute to improved economic conditions - fiscal expenditure is expected to increase from CLP29,723bn in 2009 to CLP33,273bn in 2010 - and an increase in GDP growth rates (from -1.53% in 2009 to 5.20% in 2010).

Chile's recovery from the global recession has been aided by an unprecedented monetary stimulus. As a result, private consumption surged 10.7% year-on-year (y-o-y) in Q210, marking the fastest rate of expansion since the first quarter of 1996. The robust increase in domestic demand has been reflected by retail sales, expanding by an average 19.8% y-o-y between April and June 2010. Similarly, a combination of post-earthquake reconstruction efforts and the ongoing expansion of production capacities helped push growth in gross fixed capital formation (GFCF) to 28.6% y-o-y, a remarkable turnaround on the average 15.1% y-o-y contraction posted in 2009. BMI projects Chile's real GDP to expand by 5.2% in 2010 and 4.5% in 2011. With unemployment set to steadily decrease and banks increasingly willing to extend new credit, BMI expects pharmaceutical retailers to benefit from increasing private consumption levels through the medium term.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/88491_chile_pharmaceuticals_he...

Partial Table of Contents:

Executive Summary
SWOT Analysis
- Chile Pharmaceuticals And Healthcare Industry SWOT
- Chile Political SWOT
- Chile Economic SWOT
- Chile Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas - Regional Pharmaceutical Business Environment Ratings, Q410
- Rewards
- Risks To Realisation Of Returns
Chile - Market Summary
Regulatory Regime
- Recent Regulatory Developments
- Intellectual Property
- IP Deficiencies
- Recent IP Developments
- Trade Agreements
- Pricing Regime
- Reimbursement Regime
Industry Developments
- Epidemiology
- Table: DALYs Lost To All Diseases And Injuries Per 100,00 Population In Select South American Countries
- Healthcare Sector
- Healthcare Insurance
- Pharmaceutical Retail Sector
- Distribution
- Research and Development
- Clinical Trials
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Chile - Economic Activity
- Prescription Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data
- Key Risks To BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Sector
- Domestic Industry
- Table: Latin American Regulations On Bioequivalence And GMP
- Foreign Industry
- Recent Pharmaceutical Industry Developments
- OTC Medicines
Company Monitor
- Local Companies
- Laboratorios Chile (LabChile)
- Laboratorios Andromaco
- Leading Multinationals
- Pfizer
- Novartis
- Sanofi-Aventis
- GlaxoSmithKline (GSK)
- Merck & Co
Country Snapshot: Chile Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=8849...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.